Abstract: Method for suppressing adhesion of the intestines or therapeutic treatment of adhesion of the intestines comprising administering to a patient in need thereof a therapeutically effective amount of 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl]benzoic acid. There is also provided a medicament for suppressing adhesion of the intestines and/or therapeutic treatment of bowel diseases such as inflammatory bowel diseases, including Crohn's disease, which comprises as an active ingredient a retinoid such as, for example, 4-[(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl]benzoic acid.
Abstract: A composition is described that can be used in prevention or treatment of patients having impaired gastro-intestinal tract function. The composition comprises free amino acids including about 9.0% to about 17.0% glutamic acid. Methods of treatment of impaired gastro-intestinal tract function are described.
Type:
Grant
Filed:
April 28, 2006
Date of Patent:
November 29, 2011
Assignee:
Nestec S.A.
Inventors:
Constance Whippie, Olivier Ballevre, Julio Boza, Paul-André Finot
Abstract: A method for treating a digestive ulcer of the small intestine or stomach is disclosed with a non-purine xanthine oxidase inhibitor that is a carboxylic acid compound, wherein the non-purine xanthine oxidase inhibitor is a carboxylic acid compound of formula (I) or its salt and wherein the terms of formula (I) are herein defined:
Type:
Grant
Filed:
February 22, 2007
Date of Patent:
November 29, 2011
Assignee:
Astellas Pharma Inc.
Inventors:
Masakatsu Kawakami, Yoshihiro Keto, Ken Ikeda, Mari Fukuda, Junji Sato
Abstract: Provided is a pharmaceutical composition for external use which includes the following components: 1) luliconazole and/or a salt thereof; 2) N-methyl-2-pyrollidone; and 3) benzyl alcohol and/or diester of a dibasic acid. The diester of the dibasic acid is a diethyl ester or a diisopropyl ester of a dibasic acid having 6-10 carbon atoms. The pharmaceutical composition is useful for the treatment of a mycotic disease such as foot trichophytosis, trichophytosis corporis, trichophytosis on a hard keratin or hyperkeratotic portion, onychomycosis, particularly on a nail, or dermatomycosis.
Abstract: The present invention is directed to a method of treating systemic lupus erythematosus comprising administering a compound of formula (I) wherein R1 is selected from the group consisting of CF3, a C1-C5 alkyl, and (CH2)nR4, wherein n is between 0 and 4; R2 is selected from the group consisting of (CH2)mR4 and (CH2)mAr, wherein m is between 0 and 5; R3 is selected from the group consisting of hydrogen and methyl; R4 is selected from the group consisting of phenyl, OH, a C1-C3 alkoxy, a C1-C3 dialkylamino, piperidino, and N-methylpiperazino; Ar represents ?wherein X is selected from the group consisting of F, C1, a C1-C3 alkoxy, and CF3. The compounds can be used in combination with a second compound used in the treatment of systemic lupus erythematosus.
Type:
Grant
Filed:
March 6, 2007
Date of Patent:
November 15, 2011
Assignee:
Centre National de la Recherche Scientifique (CNRS)
Abstract: A composition may include a pharmaceutical carrier and an amount, therapeutically effective for the treatment of a retinal disease, of CLT-005 (1-acetyl-5-hydroxyanthracene-9,10 -dione), wherein the retinal disease is characterized by at least one of inflammation, angiogenesis, or neovascularization, and wherein the composition is prepared for administration intravitreally. The composition may be administered intravitreally to a subject's eye.
Abstract: A method for therapy of diarrhea-predominant irritable bowel disorders comprising as an effective ingredient a morphinan derivative having a nitrogen-containing cyclic group or a pharmaceutically acceptable acid addition salt thereof is disclosed. The method for therapy of diarrhea-predominant irritable bowel disorders comprises as an effective ingredient a morphinan derivative or a pharmaceutically acceptable acid addition salt thereof, having a specific structure, such as N-(17-cyclopeopylmethyl-4,5?-epoxy-3,14-dihydroxy-morphinan-6?-yl)-3,4,5,6-tetrahydrophthalimide tartaric acid salt (Compound 10).
Type:
Grant
Filed:
November 7, 2006
Date of Patent:
November 15, 2011
Assignee:
Toray Industries, Inc.
Inventors:
Koji Kawai, Morihiro Fujimura, Sayoko Kanie, Yohei Noro
Abstract: The invention provides compositions comprising 4-APAA compounds and methods for treating disorders involving inflammation of the intestinal system, such as inflammatory bowel disease. The methods and compositions of the invention also include combinations of 4-APAA compounds and 5-ASA compounds for treatment of such disorders.
Abstract: A method for treating a liver disease such as hepatitis, comprising administering to a patient having the liver disease, an effective amount of a diarylsulfide or diarylether derivative having 2-amino-1,3-propanediol structure, and represented by the following formula (1): or a pharmaceutically acceptable salt thereof.
Abstract: Compositions comprising eicosapentaenoic acid and docosahexaenoic acid in a ratio of from 1.2 to 2 are administered to felines to treat feline inflammatory bowel disease.
Type:
Grant
Filed:
December 29, 2006
Date of Patent:
November 1, 2011
Assignee:
Hill's Pet Nutrition, Inc.
Inventors:
Christina Khoo, William David Schoenherr, Kathy Lynn Gross
Abstract: Substituted fused bicyclic pyrimidine compounds having an amide-substituted pyridylamine group at C-4 of the pyrimidine ring are useful in the treatment of conditions associated with HCV.
Type:
Grant
Filed:
March 27, 2006
Date of Patent:
October 4, 2011
Assignee:
Tibotec Pharmaceuticals Ltd.
Inventors:
Kenneth Alan Simmen, Dominique Louis Nestor Ghislain Surleraux, Tse-I Lin, Oliver Lenz, Pierre Jean-Marie Bernard Raboisson, Sarvajit Chakravarty, Barry Patrick Hart
Abstract: The present invention relates to a method for treating or alleviating migraines, by administering to a patient in need thereof compound (I), or salts thereof, or pharmaceutical preparations thereof comprising mixtures of compound (I) or salts thereof with pharmaceutically-acceptable diluents wherein: R represents —NHC(O)OR3; and R3 represents methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tert-butyl or phenylmethyl.
Abstract: A method of treating irritable bowel syndrome in a patient suffering therefrom comprising: administering an effective amount of a compound selected from compound 1, its metabolite 2 and pharmaceutically acceptable salts or esters thereof:
Type:
Grant
Filed:
May 7, 2010
Date of Patent:
September 27, 2011
Assignee:
Medicinova, Inc.
Inventors:
Kenneth Walter Locke, Charles G. Smith, Takashi Kiyoizumi
Abstract: The present invention relates to a method of treating gut pain or gut discomfort related or linked to gut muscular abnormalities comprising the step of administering to a human or an animal having gut pain or gut discomfort an effective amount of a selected probiotic.
Type:
Grant
Filed:
July 23, 2003
Date of Patent:
September 20, 2011
Assignee:
Nestec S.A.
Inventors:
Irène Corthesy-Theulaz, Elena Verdu de Bercik, Premysl Bercik, Stephen Michael Collins
Abstract: The present invention relates to a preventive and/or therapeutic agent for a glomerular disease containing, as active ingredients, pitavastatin or a salt thereof and candesartan cilexetil or a salt thereof. The agent of the present invention exhibits an excellent effect in the prevention and/or therapy of a glomerular disease.
Type:
Grant
Filed:
October 25, 2005
Date of Patent:
September 20, 2011
Assignees:
Kowa Co., Ltd., Nissan Chemical Industries, Ltd.
Abstract: The invention relates to a pharmaceutical preparation comprising levothyroxine sodium, gelatine and fillers, which is free of organic solvent residues.
Abstract: The invention relates to treating colorectal polyps and precancercerous colorectal changes by topical administration of immunomodulating drugs of the imidazoquinoline family, such as imiquimod (1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine), resiquimod (4-amino-?,?-dimethyl-2-ethoxymethyl-1H-imidazo[4,5-c]quinoline-1-ethanol), sotirimod (2-methyl-1-(2-methylpropyl)-1H-imidazo[4,5-c][1,5]naphthyridin-4-amine).
Type:
Grant
Filed:
January 14, 2009
Date of Patent:
August 30, 2011
Assignee:
Meda Pharma GmbH & Co. KG
Inventors:
Joachim Maus, Istvan Szelenyi, Ursula Petzold
Abstract: A method of treating esophageal cancer, containing the step of administering to a patient suffering from esophageal cancer, a compound or a salt thereof, wherein the compound is: N-(2-fluoro-4-{[2-({[4-(4-methylpiperazin-1-yl)piperidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N?-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, N-[4-({2-[(azetidin-1-ylcarbonyl)amino]pyridin-4-yl}oxy)-2-fluorophenyl]-N?-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, N-{2,5-difluoro-4-[(2-{[(3-hydroxyazetidin-1-yl)carbonyl]amino}pyridin-4-yl)oxy]phenyl}-N?-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, N-(2,5-difluoro-4-{[2-({[4-(4-methylpiperazin-1-yl)piperidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N?-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, N-(2,5-difluoro-4-{[2-({[methyl(1-methyl-piperidin-4-yl)amino]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N?-(4-fluorophenyl)-cyclopropane-1,1-dicarboxamide, or N-(2,5-difluoro-4-{[2-({[3-(hydroxymethyl)azetidin-1-yl]carbonyl}amino)pyridin-4-yl]oxy}phenyl)-N?-(4-fluorophenyl)